Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Table 3

Selective studies evaluating therapy related risk of lymphoma in RA patients.

Author	Year	Therapy	Disease	Sample population	Measure of risk	Comparison group	Risk
Wolfe and Michaud [48]	2007	Inf., Etan., and Ana.	RA	19,591	OR	All RA patients not on anti-TNF therapy	1.0 (0.6, 1.8)
		Anti-TNF therapy plus MTX	RA		OR	MTX therapy alone	1.1 (0.6, 2.0)
Geborek et al. [49]	2005	Inf. and Etan.	RA	757 (anti-TNF group) versus 800 (conventional treatment)	AHR	Anti-TNF alpha naive RA patients	5.0 (0.9, 27.9)
Askling et al. [50]	2005	Inf., Etan., and Ana.	RA	4160	ARR	All RA patients/all treatments	1.1 (0.6, 2.1)
Setoguchi et al. [51]	2006	Inf., Etan., and Ana.	RA	1152 biologic users versus 7306 MTX users	AHR	RA patients with MTX use only	1.11 (0.51, 2.37)
Askling et al. [18]	2009	Inf., Etan., and Ana.	RA	6604	ARR	Anti-TNF alpha naive RA patients	1.35 (0.82, 2.11)
Wolfe and Michaud [52]	2004	MTX	RA	18,572	SIR	General population	1.7 (95% CI 0.9–3.2)
		Infliximab and etanercept			SIR		2.9 (95% CI 1.7–4.9)
Buchbinder et al. [53]	2008	MTX	RA	459	SIR	General population	5.1 (2.2–10.0)

Inf.: infliximab; Etan.: etanercept; Ana.: anakinra; RA: rheumatoid arthritis; MTX: methotrexate; ARR: adjusted relative risk; AOR: adjusted odds ratio; AHR: adjusted hazard ratio; SIR: standardized incidence ratio.